Diabetes Research and Clinical Practice
Volume 95, Issue 1 , Pages 10-18 , January 2012

Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland

  • Jyrki K. Mäkelä

      Affiliations

    • Mehiläinen Lahti, Sibeliuksenkatu 6C, Lahti, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 44 077 1654; fax: +358 3 8255 290.
    • ,
  • Christine Schmüser

      Affiliations

    • Pohjois-Pori Health Centre, Pori, Finland
    • ,
  • Kari Askonen

      Affiliations

    • Ylitornio Health Centre, Ylitornio, Finland
    • ,
  • Tero Saukkonen

      Affiliations

    • Clinical, Medical & Regulatory Department, Novo Nordisk Farma Oy, Espoo, Finland

Received 2 February 2011 ,Revised 25 May 2011 ,Accepted 6 June 2011.

References 

  1. Malmberg K for the DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512–1515
  2. UK Prospective Diabetes Study Group (UKPDS Group). Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  3. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007;27:1102–1110
  4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203
  5. Duodecim . Finnish current care guideline: the treatment of diabetes. Duodecim. 2007;123:1490–1520
  6. American Diabetes Association (ADA) . Standards of medical care in diabetes––2009. Diabetes Care. 2009;32(Suppl 1):S13–S61
  7. Valle T, Tuomilehto J. People with diabetes and metabolic control in Finland in the years 2000–2001. DHEKO Report; 2004. p. 1.
  8. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10:S1–S10
  9. El-Kebbi IM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Phillips LS. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care. 2004;27:335–339
  10. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care. 2003;26:688–696
  11. Meigs JB, Nathan DM, D’Agostino RB, Wilson PW Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845–1850
  12. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–924
  13. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822–1826
  14. Monnier L, Colette C, Lapinski H. Global assessment for quality and safety of control in type 2 diabetic patients. Eur J Clin Invest. 2004;34:37–42
  15. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 diabetes. Diabetes Care. 2005;28:260–265
  16. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527–532
  17. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin. 2009;25:2887–2894
  18. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8:58–66
  19. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul , et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–1730
  20. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes Metab. 2009;11:45–52
  21. Breum L, Almdal T, Eiken P, Lund P, Christiansen E, on behalf of the Danish BIAsp Study Group . Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study. Rev Diabet Stud. 2008;5:154–162
  22. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10:212–222
  23. Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23:3209–3214
  24. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63:522–531
  25. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010;95:2240–2247
  26. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016–1021
  27. Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12:491–501
  28. Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin Plus Oral ageNts). Diabetes Obes Metab. 2007;11:27–32
  29. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616–625
  30. Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract. 2011;65:165–171

☆ Clinicaltrials.gov registration: NCT00696995.

PII: S0168-8227(11)00304-4

doi: 10.1016/j.diabres.2011.06.006

Diabetes Research and Clinical Practice
Volume 95, Issue 1 , Pages 10-18 , January 2012

Article Tools

* Image Usage & Resolution